Cargando…
A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients
The anticancer immune response is shaped by immunogenic cell stress and death pathways. Thus, cancer cells can release danger-associated molecular patterns that act on pattern recognition receptors expressed by dendritic cells and their precursors to elicit an antitumor immune response. Here, we inv...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037530/ https://www.ncbi.nlm.nih.gov/pubmed/35481288 http://dx.doi.org/10.1080/2162402X.2022.2059878 |
_version_ | 1784693742632960000 |
---|---|
author | Le Naour, Julie Sztupinszki, Zsofia Carbonnier, Vincent Casiraghi, Odile Marty, Virginie Galluzzi, Lorenzo Szallasi, Zoltan Kroemer, Guido Vacchelli, Erika |
author_facet | Le Naour, Julie Sztupinszki, Zsofia Carbonnier, Vincent Casiraghi, Odile Marty, Virginie Galluzzi, Lorenzo Szallasi, Zoltan Kroemer, Guido Vacchelli, Erika |
author_sort | Le Naour, Julie |
collection | PubMed |
description | The anticancer immune response is shaped by immunogenic cell stress and death pathways. Thus, cancer cells can release danger-associated molecular patterns that act on pattern recognition receptors expressed by dendritic cells and their precursors to elicit an antitumor immune response. Here, we investigated the impact of single nucleotide polymorphisms (SNPs) in genes affecting this cancer-immunity dialogue in the context of head and neck squamous cell carcinoma (HNSCC). We observed that homozygosity for a loss-of-function SNP (rs2241880, leading to the substitution of a threonine residue in position 300 by an alanine) affecting autophagy related 16 like 1 (ATG16L1) is coupled to poor progression-free survival in platinum-treated HNSCC patients. This result was obtained on a cohort of patients enrolled at the Gustave Roussy Cancer Campus and was validated on an independent cohort of The Cancer Genome Atlas (TCGA). Homozygosity in rs2241880 is well known to predispose to Crohn’s disease, and epidemiological associations between Crohn’s disease and HNSCC have been reported at the levels of cancer incidence and prognosis. We speculate that rs2241880 might be partially responsible for this association. |
format | Online Article Text |
id | pubmed-9037530 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-90375302022-04-26 A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients Le Naour, Julie Sztupinszki, Zsofia Carbonnier, Vincent Casiraghi, Odile Marty, Virginie Galluzzi, Lorenzo Szallasi, Zoltan Kroemer, Guido Vacchelli, Erika Oncoimmunology Original Research The anticancer immune response is shaped by immunogenic cell stress and death pathways. Thus, cancer cells can release danger-associated molecular patterns that act on pattern recognition receptors expressed by dendritic cells and their precursors to elicit an antitumor immune response. Here, we investigated the impact of single nucleotide polymorphisms (SNPs) in genes affecting this cancer-immunity dialogue in the context of head and neck squamous cell carcinoma (HNSCC). We observed that homozygosity for a loss-of-function SNP (rs2241880, leading to the substitution of a threonine residue in position 300 by an alanine) affecting autophagy related 16 like 1 (ATG16L1) is coupled to poor progression-free survival in platinum-treated HNSCC patients. This result was obtained on a cohort of patients enrolled at the Gustave Roussy Cancer Campus and was validated on an independent cohort of The Cancer Genome Atlas (TCGA). Homozygosity in rs2241880 is well known to predispose to Crohn’s disease, and epidemiological associations between Crohn’s disease and HNSCC have been reported at the levels of cancer incidence and prognosis. We speculate that rs2241880 might be partially responsible for this association. Taylor & Francis 2022-04-17 /pmc/articles/PMC9037530/ /pubmed/35481288 http://dx.doi.org/10.1080/2162402X.2022.2059878 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Le Naour, Julie Sztupinszki, Zsofia Carbonnier, Vincent Casiraghi, Odile Marty, Virginie Galluzzi, Lorenzo Szallasi, Zoltan Kroemer, Guido Vacchelli, Erika A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients |
title | A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients |
title_full | A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients |
title_fullStr | A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients |
title_full_unstemmed | A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients |
title_short | A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients |
title_sort | loss-of-function polymorphism in atg16l1 compromises therapeutic outcome in head and neck carcinoma patients |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037530/ https://www.ncbi.nlm.nih.gov/pubmed/35481288 http://dx.doi.org/10.1080/2162402X.2022.2059878 |
work_keys_str_mv | AT lenaourjulie alossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients AT sztupinszkizsofia alossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients AT carbonniervincent alossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients AT casiraghiodile alossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients AT martyvirginie alossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients AT galluzzilorenzo alossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients AT szallasizoltan alossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients AT kroemerguido alossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients AT vacchellierika alossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients AT lenaourjulie lossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients AT sztupinszkizsofia lossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients AT carbonniervincent lossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients AT casiraghiodile lossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients AT martyvirginie lossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients AT galluzzilorenzo lossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients AT szallasizoltan lossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients AT kroemerguido lossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients AT vacchellierika lossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients |